Alexion Pharma (ALXN) Tops Q3 EPS by 28c, Revenues Beat; Boosts FY18 EPS/Revenue/Operating Margin Outlook

Alexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $2.02, $0.28 better than the analyst estimate of $1.74. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.02 billion.

• 3Q18 total revenues of $1,026.5 million, a 20 percent increase over 3Q17 and a 26 percent volume increase
• 3Q18 GAAP diluted EPS of $1.47 per share; non-GAAP diluted EPS of $2.02 per share
• Updated 2018 full-year guidance given the strength of the business
• Positive topline Phase 3 data for eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD); regulatory submissions planned for early 2019
• Announced agreement to acquire Syntimmune and collaboration with Dicerna

"We continued to execute on our key objectives this quarter, further strengthening our core business and again delivering strong top and bottom-line growth," said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. "Following the groundbreaking Phase 3 results of eculizumab in NMOSD, we are moving quickly to prepare global regulatory submissions, which could make it the first approved therapy for patients with this devastating disease. Our teams continue to demonstrate launch excellence with sustained growth of Soliris® in gMG. In addition, we made significant progress diversifying our portfolio with the anticipated acquisition of Syntimmune and our collaboration with Dicerna. We continue to look for additional opportunities while advancing internal programs to position us for further long-term growth."

GUIDANCE:

Alexion Pharma sees FY2018 EPS of $7.45-$7.60, versus the consensus of $7.24. Alexion Pharma sees FY2018 revenue of $4.02-4.05 billion, versus the consensus of $4.04 billion.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c